Form 4: Relay Therapeutics Executive Peter Rahmer Reports Stock Sale and Purchase

Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, reports the sale of 245 shares to cover tax obligations and the purchase of 2,108 shares under the company's Employee Stock Purchase Plan.

Summary

• Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, reported a transaction involving the company's common stock.
• On June 27, 2024, Rahmer sold 245 shares at $6.26 per share to cover income tax withholding obligations related to the vesting of restricted stock units.
• On June 30, 2024, Rahmer acquired 2,108 shares at $5.54 per share under the company's Employee Stock Purchase Plan (ESPP).
• Following these transactions, Rahmer beneficially owns 434,288 shares of Relay Therapeutics common stock, including 383,442 shares underlying restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected, with the ESPP purchase slightly positive as it indicates the executive's continued investment in the company.

Positives

• The purchase of shares through the ESPP demonstrates the executive's investment in the company's future.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are relatively small in scale.

Key Dates